OHTA'S ISAN STOMACH POWDER 497 MG / 1.3 G — DIN 02005085
CALCIUM CARBONATE : 497 MG / 1.3 G SODIUM BICARBONATE : 600 MG / 1.3 G · MAIZUN-CALBER (CANADA) LTD. · POWDER · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is OHTA'S ISAN STOMACH POWDER?
OHTA'S ISAN STOMACH POWDER 497 MG / 1.3 G contains CALCIUM CARBONATE : 497 MG / 1.3 G SODIUM BICARBONATE : 600 MG / 1.3 G. It is listed in the Health Canada Drug Product Database under DIN 02005085, held by MAIZUN-CALBER (CANADA) LTD., supplied as POWDER for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 28-Aug-1999. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
Is there a generic Antacids With Sodium Bicarbonate in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
7 holders have a Canadian DIN containing Antacids With Sodium Bicarbonate, across 9 DINs, of which 0 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BRIOSCHI, INC. | 2 | 0 | BRIOSCHI EFFERVESCENT ANTACID - 1.8GM/6GM, BRIOSCHI EFFERVESCENT ANTACID PWR 280.3MG/GM | No marketed DIN |
| D.C. LABS LIMITED | 2 | 0 | SODIUM BICARBONATE TAB 300MG, SODIUM BICARBONATE TAB 600MG | No marketed DIN |
| MAIZUN-CALBER (CANADA) LTD. | 1 | 0 | OHTA'S ISAN STOMACH POWDER | No marketed DIN |
| REGAL PHARMS, DIVISION OF BRADCAN CORPORATION | 1 | 0 | BAKING SODA USP | No marketed DIN |
| ROTER PHARMACEUTISCHE FABRIEK | 1 | 0 | ROTER TABLETS | No marketed DIN |
| SABEX INC | 1 | 0 | NORMO GASTRYL | No marketed DIN |
| TOWER LABORATORIES LTD | 1 | 0 | BROMO SELTZER | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 497 MG / 1.3 G |
|---|---|
| Dosage form | POWDER |
| Route | ORAL |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Antacids With Sodium Bicarbonate |
|---|---|
| ATC code | A02AH |
| AHFS class | 56:04.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02005085 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2005085 |
| Brand name | OHTA'S ISAN STOMACH POWDER |
| Generic / active ingredient | CALCIUM CARBONATE : 497 MG / 1.3 G SODIUM BICARBONATE : 600 MG / 1.3 G |
| Market authorization holder | MAIZUN-CALBER (CANADA) LTD. |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| ATC code | A02AH |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A02AH |
| Current status | CANCELLED POST MARKET |
| Status date | 28-Aug-1999 |
| Original market date | 1997-06-20 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 9 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| BAKING SODA USP | 100 % | POWDER | REGAL PHARMS, DIVISION OF BRADCAN CORPORATION | CANCELLED POST MARKET | 00641634 |
| BRIOSCHI EFFERVESCENT ANTACID - 1.8GM/6GM | 1.8 G / 6 G | POWDER (EFFERVESCENT) | BRIOSCHI, INC. | CANCELLED POST MARKET | 02230226 |
| BRIOSCHI EFFERVESCENT ANTACID PWR 280.3MG/GM | 269 MG | POWDER (EFFERVESCENT) | BRIOSCHI, INC. | CANCELLED POST MARKET | 00677450 |
| BROMO SELTZER | 2.667 G / 7.3 G | GRANULES | TOWER LABORATORIES LTD | CANCELLED POST MARKET | 02241892 |
| NORMO GASTRYL | 195 MG | TABLET (EFFERVESCENT) | SABEX INC | CANCELLED POST MARKET | 00570826 |
| ROTER TABLETS | 25 MG | TABLET | ROTER PHARMACEUTISCHE FABRIEK | CANCELLED POST MARKET | 00173797 |
| SODIUM BICARBONATE TAB 300MG | 300 MG | TABLET | D.C. LABS LIMITED | CANCELLED POST MARKET | 00093068 |
| SODIUM BICARBONATE TAB 600MG | 600 MG | TABLET | D.C. LABS LIMITED | CANCELLED POST MARKET | 00221619 |
2 · Same class — other molecules in ATC A02AH
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Antacids With Sodium Bicarbonate | BAKING SODA USP · BRIOSCHI EFFERVESCENT ANTACID - 1.8GM/6GM · BRIOSCHI EFFERVESCENT ANTACID PWR 280.3MG/GM · BROMO SELTZER · +5 more | 9 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A02A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A02AF | Magaldrate And Antiflatulents · Ordinary Salt Combinations And Antiflatulents | 59 | 4 |
| A02AX | Antacids, Other Combinations | 14 | 2 |
| A02AA | Magnesium Carbonate · Magnesium Hydroxide | 14 | 0 |
| A02AB | Aluminium Hydroxide | 1 | 0 |
| A02AC | Calcium Carbonate | 16 | 0 |
| A02AD | Magaldrate · Ordinary Salt Combinations | 47 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.